ClinicalTrials.gg

Program

HBI-002

A development code.

Its studies are mostly in Anemia, Sickle Cell · Parkinson Disease, led by Hillhurst Biopharmaceuticals.

Furthest: phase 2, since Nov 10, 20233 company-led studies, 1 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hillhurst Biopharmaceuticals31 open or runningphase 2since Nov 10, 2023Apr 22, 2019Dec 31, 2026phase 2 · NCT07005180

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 22, 2019First study: phase 1 study in Anemia, Sickle CellFirst studyNCT03926819 · 20 enrolled · United States
  2. Nov 10, 2023Phase 2 study in Anemia, Sickle CellNCT06144749 · 13 enrolled · Panama
  3. Feb 28, 2025Phase 2 study in Parkinson DiseaseNCT07005180 · 36 planned · United States

Ahead

  1. Dec 31, 2026Primary completion: phase 2 study in Parkinson DiseaseNCT07005180

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07005180Parkinson Disease · United States2RecruitingDec 31, 202636
NCT06144749Anemia, Sickle Cell · Panama2CompletedJun 30, 202613
NCT03926819Anemia, Sickle Cell · United States1CompletedApr 26, 202320

How it is read

Names in the registry

  • “HBI-002”, 3 entries

Codes read as this program: HBI002.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.